Ciuleanu, Tudor-Eliade
Ahmed, Samreen
Kim, Joo-Hang
Mezger, Jörg
Park, Keunchil
Thomas, Michael
Chen, Jihong
Poondru, Srinivasu
VanTornout, Jan M
Whitcomb, Debbie
Blackhall, Fiona
Article History
Received: 31 May 2016
Revised: 20 June 2017
Accepted: 22 June 2017
First Online: 3 August 2017
Competing interests
: Tudor-Eliade Ciuleanu has served on an advisory board for Astellas, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, Merck, Merck Sharp and Dohme, Pfizer, Roche, and Boehringer Ingelheim. JHK declares grant funding from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, and Roche. KP has served in an advisory role for Astellas and Roche. JC, SP, JMV, and DW were employed with Astellas at the time of the study. SA, JM, MT, and FB have no conflicts to disclose.